Intuitive Surgical, which makes robotic-surgery systems, says the rollout of weight-loss drugs like Ozempic is pressuring demand for bariatric surgeries in the short term, but the company expects those people to eventually opt for a weight-loss surgery. “In the short-term we will see patients who are considering or are in the pipeline for bariatric surgery going to try the drug,” Chief Medical Officer Myriam Curet tells analysts on a conference call. “However, given compliance issues, cost, side effects, we expect that many of them will not stay on the drugs for longer than a year or two, and at that time will consider bariatric surgery.” Longer term, Curet says the company expects interest in weight loss to grow and boost demand for surgeries. Shares slip 1.6%.